New Parkinson's drug candidate passes first safety check in healthy volunteers
NCT ID NCT06088784
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested a new oral drug, ATH-399A, in 76 healthy adults to see if it is safe and how the body processes it. The goal is to gather information needed to develop a treatment for Parkinson's disease. Participants took single or multiple doses, and researchers also checked if food affected the drug. No direct benefit was expected for volunteers.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Syneos Quebec Canada
Québec, QC G1P 0A2, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug pass its first safety hurdle?
- Can a new drug play nice with common medicines? a trial investigates
- Could a new pill quiet chronic pain? early trial puts it to the test
- Brain waves under pressure: can light uncover the signature of mental work?
- Can acting as patients teach nurses to truly listen?
- Who decides for you? survey asks incarcerated older adults